Rucaparib — a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer

Rucaparib (PARP inhibitor) as treatment for metastatic castration-resistant prostate cancer associated with germline *BRCA1/2* mutations

An evaluation of rucaparib, the first FDA-approved PARP inhibitor for germline BRCA-associated metastatic castration-resistant prostate cancer (mCRPC), synthesizes efficacy and safety data in this germline indication. Rucaparib efficacy relies on prior identification of germline BRCA1/2 mutations, reinforcing the importance of constitutional genetic testing in men with advanced prostate cancer. These data consolidate the role of PARP inhibitors in managing BRCA carriers with prostate cancer.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

The extension of PARP inhibitor indications to germline BRCA prostate cancer represents a major advance in male cancer genetics. Oncogeneticists play a key role in identifying male BRCA carriers before or at the time of advanced prostate cancer diagnosis. An additional argument for systematic constitutional testing in this context.